Insys Therapeutics successfully completes safety and PK study of cannabidiol oral solution
Insys Therapeutics announced that it has successfully completed its Phase 1/Phase 2 safety and pharmacokinetic study in pediatric subjects with treatment-resistant epilepsy. The clinical trial evaluated multiple ascending doses of Insys’ CBD with three cohorts. May 24, 2016